Published guidance, NICE advice and quality standards | Guidance

Showing 301 to 310 of 875

Sort by

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma	TA818	17 August 2022	17 August 2022
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies	TA819	17 August 2022	17 August 2022
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs	TA815	10 August 2022	10 August 2022
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer	TA816	10 August 2022	10 August 2022
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence	TA817	10 August 2022	10 August 2022
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors	TA813	3 August 2022	3 August 2022
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis	TA814	3 August 2022	3 August 2022
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer	TA812	3 August 2022	3 August 2022
Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal)	TA811	27 July 2022	27 July 2022
Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease	TA809	20 July 2022	20 July 2022